Conclusion of a non-exclusive discount agreement pursuant to § 130a para. 8 SGB V for the active ingredient Cladribine (OBO), ATC L04AA40 for the period 01.12.2024 - 30.11.2026
Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Cladribin (OBO), ATC L04AA40 für die Zeit 01.12.2024 - 30.11.2026
Germany · Hamburg · how to bid here →
Your path to submission
- Deadline: 5 October at 12:00 — 1 day left.
- You submit on Vergabemarktplatz (cosinex) — not here and not by e-mail. ↗ Free bidder account on the cosinex platform required (created instantly); offers go through the bidding tool, usually plain text form suffices — no qualified signature. Sort out account and signature first — not on submission day.
- Offer and evidence in: DEU.
- Collect your evidence — use the eligibility analysis above: it lists the requirements and, for known certificates, how to get them.
Clement What the numbers say about this buyer
- The median procedure drew 9 bids (3,267 procedures with a bid count); 7% ended with a single bidder. Sector: median 2 bids.n = 3,267
- In this sector the buyer awards roughly every month (2862 awards, most recently June 2026) — by that rhythm the next award was due around July 2026. The last award went to Sanofi-Aventis Deutschland GmbH.n = 2,862
- 81% of this buyer's awards went to companies that had already won here before (3,321 awards since 2017, spread over 567 companies). That is well above the sector norm (62%) — newcomers have a harder time here than elsewhere.n = 3,321 awards since 2017
- 83% of the bids received came from small and medium-sized enterprises (15 procedures with a bid mix). Sector: 38%.n = 15
- The award came in at a median 79% of the estimated value (6 awards with both estimate and value) — pricing at the estimate is usually too high here. Sector: 87%.n = 6
From this buyer's documented awards; comparison values from the same sector and country. Not a forecast, not legal advice. As of 01/10/2026.
Foreign bidders
In Germany · Medical equipment & pharma, 265 contracts went to foreign companies over the last 3 years (of 22,111 recorded awards) — mostly from Austria, Netherlands, France.
Typical field: median 11 (from 4,142 awards).
What the buyer is looking for
DAK-Gesundheit assumes that this procedure does not fall within the scope of antitrust law due to a lack of a selection decision and therefore the non-discriminatory access of all pharmaceutical companies. It shall terminate automatically upon the entry into force of the exclusive agreement for Cladribine, ATC L04AA40, as a result of a formal
What you must prove — eligibility criteria
From the notice of the same procedure on TED — Tenders Electronic Daily.
Contract
Who has won here before
| Company | Awards | Period |
|---|---|---|
| Abacus Medicine A/S · Kopenhagen | 184 | 2022–2026 |
| kohlpharma GmbH · Merzig | 168 | 2022–2026 |
| EurimPharm Arzneimittel GmbH · Saaldorf-Surheim | 134 | 2022–2026 |
| CC Pharma GmbH · Densborn | 131 | 2022–2025 |
| Orifarm GmbH · Leverkusen | 121 | 2015–2025 |
How often this buyer tenders this
Who knows the rhythm prepares instead of reacting.
How to bid
Guide: how to apply on cosinex Vergabemarktplatz / DTVP → Registration, signature, fees — from the operator's bidder manual.